Beta-interferons counteract a few of the activities of the disease fighting capability.

A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease A trial of beta-interferon-1a in inclusion-body myositis has failed to find benefit from the drug in this disease. Beta-interferons counteract a few of the activities of the disease fighting capability, which some professionals believe can be misguided in IBM Click here . A recently available pilot trial, backed by MDA, discovered that 30 micrograms of beta-interferon-1a, given by intramuscular injection once a complete week, was secure and well tolerated by patients with IBM, but no benefit was detected.